Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arrowhead PharmaceuticalsARWR -0.45%49 Equity-to-Asset is 0.22 as of Jun. 2026, which is 63% below its 10-year median of 0.59. GuruFocus rates ARWR with a GF Score™ of 49/100 and a GF Value™ of $56.52 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Arrowhead Pharmaceuticals ranks worse than 81.07% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Arrowhead Pharmaceuticals Equity-to-Asset Related Terms
Arrowhead Pharmaceuticals Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARWR vs AXSM, MDGL, BMRN: Equity-to-Asset Comparison
For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arrowhead Pharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Arrowhead Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Arrowhead Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arrowhead Pharmaceuticals (ARWR) has a Equity-to-Asset of 0.22 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Arrowhead Pharmaceuticals and its competitors. This is 63% below median its historical median of 0.59. Over the past decade, Arrowhead Pharmaceuticals' Equity-to-Asset has ranged from 0.05 to 0.91. According to the industry distribution chart, Arrowhead Pharmaceuticals ranks #1148 out of 1416 companies in the Biotechnology industry, placing it in the top 81.1%.
Is Arrowhead Pharmaceuticals' Equity-to-Asset too high?
Arrowhead Pharmaceuticals' current Equity-to-Asset of 0.22 is 63% below median its 10-year median of 0.59. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.91. The Biotechnology industry median Equity-to-Asset is 0.68. Arrowhead Pharmaceuticals' value of 0.22 is 67.6% below this industry median. Based on the distribution chart, Arrowhead Pharmaceuticals ranks #1148 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Equity-to-Asset compare to AXSM and MDGL?
According to the Biotechnology industry distribution chart, Arrowhead Pharmaceuticals ranks #1148 out of 1416 companies for Equity-to-Asset. This places Arrowhead Pharmaceuticals in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Arrowhead Pharmaceuticals' value of 0.22 is 67.6% below this benchmark. Historically, Arrowhead Pharmaceuticals' own Equity-to-Asset has ranged from 0.05 to 0.91 over the past decade. While the company's 10-year median is 0.59 vs. the industry median of 0.68, Arrowhead Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arrowhead Pharmaceuticals's current Equity-to-Asset of 0.22 is 67.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Arrowhead Pharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arrowhead Pharmaceuticals's current Equity-to-Asset is 0.22, which is 63% below median its own 10-year median of 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $56.52, compared to a current price of $87.13 — trading 54.2% above its estimated fair value. The current Equity-to-Asset is 0.22, which is 63% below median its 10-year median of 0.59 and 67.6% below the Biotechnology industry median of 0.68. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current Equity-to-Asset is 0.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued.
The current stock price of $87.13 is trading 54.2% above its estimated GF Value™ of $56.52.
GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ARWR:
Equity-to-Asset: 0.22 (63% below median its 10-year median of 0.59)
GF Value™: $56.52 vs. price of $87.13 (54.2% above fair value)
Industry Position: 67.6% below the Biotechnology median (#1148 of 1416)
No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score
Get the complete analysis for ARWR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARWR has been successfully added to your 
